Business

mass. movers

Verastem drug wins orphan status in EU

Verastem is also studying VS-6063 as a treatment for ovarian cancer.
Globe File/2013
Verastem is also studying VS-6063 as a treatment for ovarian cancer.
Advertisement

The Cambridge cancer drug developer Verastem Inc. said its most advanced experimental treatment was awarded orphan drug status in the European Union. The decision means VS-6063 could get up to 10 years of marketing exclusivity if it is approved. Verastem is studying the drug as a treatment for mesothelioma, a cancer caused by asbestos exposure, and plans to seek marketing approval in 2015 or 2016. Verastem aims to prevent recurrences of cancer by targeting stem cells, which often survive current treatments.